{"title":"Reducing drug toxicity and costs through off-label dosing.","authors":"Mark J Ratain","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 5","pages":"328-330"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Is doublet therapy becoming a standard of care in myelofibrosis?","authors":"Raajit K Rampal","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 5","pages":"320-322"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sequencing antibody-drug conjugates in patients with hormone receptor-positive, HER2-negative metastatic breast cancer.","authors":"Javier Cortés","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 5","pages":"331-333"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Update on LAG3 and immunotherapy combinations in melanoma.","authors":"Hussein A Tawbi","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 4","pages":"229-231"},"PeriodicalIF":1.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The use of biomarkers in advanced, locally advanced, and early-stage lung cancer.","authors":"Narjust Florez","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 4","pages":"207-209"},"PeriodicalIF":1.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dual therapy: danicopan as add-on therapy to C5 inhibitors.","authors":"Catherine M Broome","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 Suppl 8 4","pages":"12-14"},"PeriodicalIF":1.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Non-clear cell renal cell carcinoma (nccRCC) is a heterogeneous category comprising approximately 25% of epithelial renal tumors. Unlike their far more common clear cell counterpart, many nccRCC subtypes are rare, poorly understood, and often aggressive in nature. Treatment options are very limited and generally have been unsuccessfully extrapolated from ccRCC trials. Numerous subtypes also seem to emerge in the context of inherited conditions or syndromes affecting younger individuals. In recent years, the World Health Organization classification of renal tumors has been frequently updated with the recognition of novel entities beyond ccRCC. The recommendations currently demonstrate a shift from morphology-based to molecularly based classification. Thus, aberrations in genes such as TFE3, TFEB, FH, SDH, SMARCB1, ELOC, and ALK define separate entities that cannot be distinguished on the basis of microscopic appearance alone. This review aims to deconstruct the general and nondescriptive term of nccRCC to provide a comprehensive presentation of specific subtypes, highlighting their epidemiologic associations and distinctive biological and clinicopathologic features. Delineating these complexities reveals areas that warrant improvement, which will translate into optimal diagnosis, treatment, and overall patient care.
{"title":"Non-clear cell renal cell carcinoma: unpacking a messy term.","authors":"Angelina Bania, Giannicola Genovese, Pavlos Msaouel","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Non-clear cell renal cell carcinoma (nccRCC) is a heterogeneous category comprising approximately 25% of epithelial renal tumors. Unlike their far more common clear cell counterpart, many nccRCC subtypes are rare, poorly understood, and often aggressive in nature. Treatment options are very limited and generally have been unsuccessfully extrapolated from ccRCC trials. Numerous subtypes also seem to emerge in the context of inherited conditions or syndromes affecting younger individuals. In recent years, the World Health Organization classification of renal tumors has been frequently updated with the recognition of novel entities beyond ccRCC. The recommendations currently demonstrate a shift from morphology-based to molecularly based classification. Thus, aberrations in genes such as TFE3, TFEB, FH, SDH, SMARCB1, ELOC, and ALK define separate entities that cannot be distinguished on the basis of microscopic appearance alone. This review aims to deconstruct the general and nondescriptive term of nccRCC to provide a comprehensive presentation of specific subtypes, highlighting their epidemiologic associations and distinctive biological and clinicopathologic features. Delineating these complexities reveals areas that warrant improvement, which will translate into optimal diagnosis, treatment, and overall patient care.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 4","pages":"253-262"},"PeriodicalIF":1.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Complement inhibitors: a significant advance in the treatment of PNH.","authors":"Ilene C Weitz","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 Suppl 8 4","pages":"5-7"},"PeriodicalIF":1.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Current utilization of molecular residual disease (MRD) testing in colorectal cancer: Q&A.","authors":"Tanios S Bekaii-Saab, Robert E Schoen","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 Suppl 7 4","pages":"10-11"},"PeriodicalIF":1.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号